Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-09-07
Butterfly Network, Inc.
Butterfly sells handheld ultrasound devices plus cloud software, workflow tools, and embedded licensing that aim to expand imaging beyond traditional cart-based systems.
ai enterprise healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Handheld imaging upside needs recurring revenue proof
A differentiated handheld ultrasound product has a credible second act as a workflow and licensing layer. The upside depends less on selling more probes than on proving software, compliance, and Embedded revenue are repeatable and durable.

Analysis

Thesis
Butterfly has a realistic path to more than double equity value by 2031 if it turns a differentiated handheld ultrasound franchise into a higher-quality mix of enterprise workflow, compliance-heavy trust software, and repeatable embedded royalties; AI helps most by widening scan volume and lowering training friction, not by replacing Butterfly’s hardware control point.
Last Economy Alignment
AI should expand who can scan, where scans happen, and how much workflow can be automated, while Butterfly still owns the probe, data capture surface, and some regulated trust layers. The upside is real, but the company is not a core compute bottleneck and its software layer could still be partially commoditized.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
This can work even without a full software-style rerating. The core question is whether Butterfly becomes more than a handheld device seller by deepening workflow, compliance, and Embedded monetization on top of the same chip platform. If that mix shift happens, revenue quality improves enough to support solid equity compounding even with some multiple compression from today’s premium small-cap medtech valuation.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly’s probe works; it does. The real risk is whether higher-quality revenue from enterprise workflow, compliance-heavy software, and Embedded royalties arrives fast enough to overcome valuation gravity, partner lumpiness, federal procurement delays, and incumbent bundling.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They own a real ultrasound chip and the clinical workflow wrapped around it, so AI can make scanning useful in more places without removing Butterfly from the loop. The risk is that larger imaging vendors or partner delays keep the software layer shallow and push the business back toward premium-device economics.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$10.67
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case